$146.50
-0.45-0.31%
Dern. MÀJ: Nov 13, 10:46 AM
Merck & rose 58.1% from $92.93 to $146.95, ahead of the S&P 500's +12.7%. Its worst day was Apr 21 (−3.9%), and its low came Nov 17 at $92.86.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Merck & closed at its lowest level of the year, 0.1% below where the year started.
−0.1% · S&P 500 −0.9%
Merck & shares rose 5.2%, while the S&P 500 rose 0.9%.
+5.2% · S&P 500 +0.9%
Story events cover the past 12 months · Times ET
EPS of $2.04 beat the $2.02 estimate on $16.4B revenue (est. $16.2B); FY revenue guidance of $65.5B–$67.0B against the $67.5B consensus.
+2.2% · S&P 500 −0.8%
EPS of $-1.28 beat the $-1.48 estimate on $16.3B revenue (est. $15.9B); FY revenue guidance of $65.8B–$67.0B against the $66.5B consensus.
−1.6% · S&P 500 +1.0%
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending
+5.6% · S&P 500 +0.4%
Merck & shares rose 4.8%, while the S&P 500 rose 0.4%.
+4.8% · S&P 500 +0.4%
EPS of $-0.13 missed the $0.23 estimate on $16.6B revenue (est. $16.4B); FY revenue guidance of $66.3B–$67.3B against the $66.7B consensus.
+0.2% · S&P 500 +1.8%
Merck & closed at its highest level of the year, 68.4% above where the year started.
+3.8% · S&P 500 +0.3%
EPS of $2.49 beat the $2.10 estimate on $18.1B revenue (est. $17.3B); FY revenue guidance of $66.8B–$67.3B against the $67.1B consensus.
+3.8% · S&P 500 −0.4%
Where it ended: a close of $146.95 on Nov 12, 2026. Up next: Q4 2026 earnings on Feb 2, 2027 (EPS est. $1.76, revenue est. $16.3B).
As of the Nov 12, 2026 close
Replay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MRK and SPY from Benzinga historical bars. Not investment advice.